Print Page  Close Window    

Investor Relations Home

Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

06/16/18A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-401
06/16/18EHA Poster
12/22/17GIAPREZA™ (angiotensin II) Update

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $12.80 with a 52 week high of $41.24 and a 52 week low of $12.61.
Price$12.80
Change (%) Stock is Down 0.6 (4.48%)
Volume150,031
Data as of 12/14/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events




There are currently no events scheduled.

Recent News


La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018

10/24/18

SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018

10/18/18

SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress

08/08/18

SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from l

Read More